Basic information of glibenclamide:

English Name：Glibenclamide
English Alias：glybenclamide；glyburide usp；Glibenclamide；Glyburide；5-chloro-n-(2-(4-((((cyclohexylamino)carbonyl)-amino)sulfonyl)phenyl)-ethyl)-2-methoxybenzamide；5-chloro-N-(2-{4-[(cyclohexylcarbamoyl)sulfamoyl]phenyl}ethyl)-2-methoxybenzamide；5-chloro-2-methoxy-N-[2-[4-(phenylcarbamoylsulfamoyl)phenyl]ethyl]benzamide；HB-419；maninil；adiab

Introduction to glibenclamide:

INN, also known as Usan, is a kind of sulfonylurea. It is also commercially available in combination with metformin, known as glucovance. Glibenclamide can inhibit glycogenolysis and gluconeogenesis of liver by increasing the level of insulin in portal vein or directly acting on liver, and reduce the generation and output of glucose in liver; it can be absorbed rapidly by oral administration, with a high protein binding rate of 95%. The blood concentration of glibenclamide reaches the peak value in 2-5 hours after oral administration, and the effect lasts for 24 hours. T1 / 2 is 10 hours. It is metabolized in the liver and excreted by the liver and kidney about 50% respectively.

Structural formula of glibenclamide:

Use of glibenclamide:

API, used as hypoglycemic drug. It is suitable for mild and moderate type Ⅱ diabetes mellitus with unsatisfactory effect of diet control alone. The β cells of the islets of Langerhans have certain insulin secretion function and have no serious complications.

Indications for glibenclamide:

It is suitable for patients with mild to moderate non insulin dependent diabetes mellitus who are not satisfied with the effect of diet control alone. The β - islet cells of patients have certain insulin secretion function and no serious complications.